SECONDARY AML

Clinical trials for SECONDARY AML explained in plain language.

Never miss a new study

Get alerted when new SECONDARY AML trials appear

Sign up with your email to follow new studies for SECONDARY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for tough blood cancers: experimental drug rebecsinib enters early trial

Disease control Not yet recruiting

This early-phase study tests a new drug called rebecsinib in 28 people with two types of blood cancer: secondary acute myeloid leukemia (sAML) that has come back or not responded to treatment, or higher-risk myelofibrosis (MF). The goal is to find the safest and most effective do…

Matched conditions: SECONDARY AML

Phase: PHASE1 • Sponsor: Aspera Biomedicines, Inc. • Aim: Disease control

Last updated May 17, 2026 07:37 UTC

SECONDARY AML

Get alerted when new SECONDARY AML trials appear

New hope for tough blood cancers: experimental drug rebecsinib enters early trial